Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Taniborbactam + Cefepime in ELF of Healthy Adults
NCT03870490Phase 1Completed
- Sponsor
- Venatorx Pharmaceuticals
- Start
- Mar 2019
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of taniborbactam in bacterial pneumonia, sponsored by Venatorx Pharmaceuticals. Primary endpoints: Pharmacokinetics in Epithelial Lining Fluid at Day 2 and Number of subjects with adverse events. Started Mar 2019; status: completed.
02
Drugs
taniborbactam
03
Conditions
bacterial pneumonia
Beyond the preview
Go deeper on NCT03870490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03870490.